191 related articles for article (PubMed ID: 21851843)
1. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.
Chung WG; Sandoval MA; Sloat BR; Lansakara-P DS; Cui Z
J Control Release; 2012 Jan; 157(1):132-40. PubMed ID: 21851843
[TBL] [Abstract][Full Text] [Related]
2. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
[TBL] [Abstract][Full Text] [Related]
3. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.
Sandoval MA; Sloat BR; Lansakara-P DS; Kumar A; Rodriguez BL; Kiguchi K; Digiovanni J; Cui Z
J Control Release; 2012 Jan; 157(2):287-96. PubMed ID: 21871505
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
Lansakara-P DS; Rodriguez BL; Cui Z
Int J Pharm; 2012 Jun; 429(1-2):123-34. PubMed ID: 22425885
[TBL] [Abstract][Full Text] [Related]
5. The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression.
Zhu S; Wonganan P; Lansakara-P DS; O'Mary HL; Li Y; Cui Z
Biomaterials; 2013 Mar; 34(9):2327-39. PubMed ID: 23261218
[TBL] [Abstract][Full Text] [Related]
6. Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.
De Angel RE; Blando JM; Hogan MG; Sandoval MA; Lansakara-P DS; Dunlap SM; Hursting SD; Cui Z
Cancer Biol Ther; 2013 Apr; 14(4):357-64. PubMed ID: 23358472
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
8. A nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activity.
Zhu S; Li X; Lansakara-P DS; Kumar A; Cui Z
J Pharm Pharmacol; 2013 Feb; 65(2):236-42. PubMed ID: 23278691
[TBL] [Abstract][Full Text] [Related]
9. Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its self-assembled nanoparticles.
Daman Z; Ostad S; Amini M; Gilani K
Int J Pharm; 2014 Jul; 468(1-2):142-51. PubMed ID: 24731731
[TBL] [Abstract][Full Text] [Related]
10. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
[TBL] [Abstract][Full Text] [Related]
11. Oral 4-(
Wang C; Zheng Y; Sand Oval MA; Valdes SA; Chen Z; Lansakara-P DS; Du M; Shi Y; Cui Z
Oncotarget; 2017 Oct; 8(52):89876-89886. PubMed ID: 29163795
[TBL] [Abstract][Full Text] [Related]
12. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
Wonganan P; Chung WG; Zhu S; Kiguchi K; Digiovanni J; Cui Z
Cancer Biol Ther; 2012 Aug; 13(10):908-14. PubMed ID: 22785206
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
14. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Bergman AM; Eijk PP; Ruiz van Haperen VW; Smid K; Veerman G; Hubeek I; van den Ijssel P; Ylstra B; Peters GJ
Cancer Res; 2005 Oct; 65(20):9510-6. PubMed ID: 16230416
[TBL] [Abstract][Full Text] [Related]
15. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
17. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
Réjiba S; Bigand C; Parmentier C; Hajri A
Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
[TBL] [Abstract][Full Text] [Related]
19. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
20. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
